Gender Differences in the One-Year Outcomes of Prasugrel versus
Ticagrelor in Acute Myocardial Infarction Treated With Primary
Angioplasty: A Posthoc Analysis of the PRAGUE-18 Study

a 2018

Gender Differences in the One-Year Outcomes of Prasugrel versus Ticagrelor in Acute Myocardial Infarction Treated With Primary Angioplasty: A Posthoc Analysis of the PRAGUE-18 Study

KALA, Petr; Zuzana MOTOVSKA; Ota HLINOMAZ; Milan HROMADKA; Jiří KNOT et. al.

Basic information

Original name

Gender Differences in the One-Year Outcomes of Prasugrel versus Ticagrelor in Acute Myocardial Infarction Treated With Primary Angioplasty: A Posthoc Analysis of the PRAGUE-18 Study

Authors

KALA, Petr (203 Czech Republic, guarantor, belonging to the institution); Zuzana MOTOVSKA (203 Czech Republic); Ota HLINOMAZ (203 Czech Republic, belonging to the institution); Milan HROMADKA (203 Czech Republic); Jiří KNOT (203 Czech Republic); Ivo VARVAROVSKY (203 Czech Republic); Jaroslav DUSEK (203 Czech Republic); Roman MIKLIK (203 Czech Republic); Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution); Stanislav SIMEK (203 Czech Republic); Marian BRANNY (203 Czech Republic); Jan MROZEK; Pavel CERVINKA (203 Czech Republic); Jiri OSTRANSKY (203 Czech Republic); Richard ROKYTA (203 Czech Republic); Frantisek TOUSEK (203 Czech Republic) and Petr WIDIMSKY (203 Czech Republic)

Edition

2018

Other information

Language

English

Type of outcome

Conference abstract

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

United States of America

Confidentiality degree

is not subject to a state or trade secret

References:

URL

Impact factor

Impact factor: 23.054

RIV identification code

RIV/00216224:14110/18:00118136

Organization unit

Faculty of Medicine

ISSN

UT WoS

000528619406361

Keywords in English

Acute Myocardial Infarction; Primary Angioplasty; Prasugrel; Ticagrelor

Abstract

In the original language

Introduction: Prasugrel and ticagrelor have shown similar primary net-clinical endpoint (cardiovascular death, spontaneous MI, stroke, severe bleeding or revascularization at day 7) and similar clinical effectivity in the PRAGUE-18 study at one year. Hypothesis: Impact of gender on the clinical outcome up to 12 months. Methods: A total of 1,230 patients with acute MI (931 males; 75.7%) treated with primary PCI were randomized to prasugrel or ticagrelor with an intended treatment duration of 12 months. Key secondary efficacy endpoint (EP) was cardiovascular death, spontaneous MI, stroke within 30 days and at one year. Results: Females were older (64.9 vs 60.9 years; p<0.001), more often hypertensive (63.2% vs 47.4%; p<0.001) and diabetics (27.8% vs 17.9%; p<0.001) and there were less smokers (58.9% vs 66.8%; p=0.015). Females suffered significantly longer time interval from symptom onset to the admission to PCI center (3.3hrs vs 2.5hrs; p=0.001). In females, the primary net-clinical EP at 7 days was not different from males (4.4% vs 3.9%; p=0.645) but at 30 days, the rate of MI and combined key efficacy EP occurred significantly more often(5.4% vs 2.7%; p=0.030 [HR 5.234; 95% CI, 1.902-14.401] and 3.3% vs 0.6%; p=0.001 [HR 2.007 95% CI, 1.072-3.759], respectively). At 12 months, there was no significant difference between the groups, though a strong trend to higher rate of MI and bleeding was found (HR 1.968, 95% CI 0.985-3.929; p=0.055 and HR 1.399 95% CI 0.970-2.020; p=0.073, respectively). End of potent P2Y12 treatment within one year was observed more often in females than males, though not statistically significant (58.5% vs 52.0%; p=0.053). No significant difference was found in the economically driven switch to clopidogrel (43.1% vs 37.8%; p=0.103). Conclusions: In the PRAGUE-18 study, the female patients were at higher baseline clinical risk, had significantly higher rate of MI and cardiovascular death/MI/stroke at 30 days and tended to have a higher rate of repeated MI and bleeding complications at 12 months. Longer pre-hospital ischemic time in females requires special attention.

Links

LM2015090, research and development project

Name: Český národní uzel Evropské sítě infrastruktur klinického výzkumu (Acronym: CZECRIN)

Investor: Ministry of Education, Youth and Sports of the CR

Cite

KALA, Petr; Zuzana MOTOVSKA; Ota HLINOMAZ; Milan HROMADKA; Jiří KNOT; Ivo VARVAROVSKY; Jaroslav DUSEK; Roman MIKLIK; Jiří JARKOVSKÝ; Stanislav SIMEK; Marian BRANNY; Jan MROZEK; Pavel CERVINKA; Jiri OSTRANSKY; Richard ROKYTA; Frantisek TOUSEK and Petr WIDIMSKY. Gender Differences in the One-Year Outcomes of Prasugrel versus Ticagrelor in Acute Myocardial Infarction Treated With Primary Angioplasty: A Posthoc Analysis of the PRAGUE-18 Study. 2018. ISSN 0009-7322.

@proceedings{1739836,
   author = {Kala, Petr and Motovska, Zuzana and Hlinomaz, Ota and Hromadka, Milan and Knot, Jiří and Varvarovsky, Ivo and Dusek, Jaroslav and Miklik, Roman and Jarkovský, Jiří and Simek, Stanislav and Branny, Marian and Mrozek, Jan and Cervinka, Pavel and Ostransky, Jiri and Rokyta, Richard and Tousek, Frantisek and Widimsky, Petr},
   keywords = {Acute Myocardial Infarction; Primary Angioplasty; Prasugrel; Ticagrelor},
   language = {eng},
   title = {Gender Differences in the One-Year Outcomes of Prasugrel versus Ticagrelor in Acute Myocardial Infarction Treated With Primary Angioplasty: A Posthoc Analysis of the PRAGUE-18 Study},
   url = {https://www.ahajournals.org/doi/10.1161/circ.138.suppl_1.16557},
   year = {2018}
}

TY  - CONF
ID  - 1739836
AU  - Kala, Petr - Motovska, Zuzana - Hlinomaz, Ota - Hromadka, Milan - Knot, Jiří - Varvarovsky, Ivo - Dusek, Jaroslav - Miklik, Roman - Jarkovský, Jiří - Simek, Stanislav - Branny, Marian - Mrozek, Jan - Cervinka, Pavel - Ostransky, Jiri - Rokyta, Richard - Tousek, Frantisek - Widimsky, Petr
PY  - 2018
TI  - Gender Differences in the One-Year Outcomes of Prasugrel versus Ticagrelor in Acute Myocardial Infarction Treated With Primary Angioplasty: A Posthoc Analysis of the PRAGUE-18 Study
KW  - Acute Myocardial Infarction
KW  - Primary Angioplasty
KW  - Prasugrel
KW  - Ticagrelor
UR  - https://www.ahajournals.org/doi/10.1161/circ.138.suppl_1.16557
L2  - https://www.ahajournals.org/doi/10.1161/circ.138.suppl_1.16557
N2  - Introduction: Prasugrel and ticagrelor have shown similar primary net-clinical endpoint (cardiovascular death, spontaneous MI, stroke, severe bleeding or revascularization at day 7) and similar clinical effectivity in the PRAGUE-18 study at one year. Hypothesis: Impact of gender on the clinical outcome up to 12 months. Methods: A total of 1,230 patients with acute MI (931 males; 75.7%) treated with primary PCI were randomized to prasugrel or ticagrelor with an intended treatment duration of 12 months. Key secondary efficacy endpoint (EP) was cardiovascular death, spontaneous MI, stroke within 30 days and at one year. Results: Females were older (64.9 vs 60.9 years; p<0.001), more often hypertensive (63.2% vs 47.4%; p<0.001) and diabetics (27.8% vs 17.9%; p<0.001) and there were less smokers (58.9% vs 66.8%; p=0.015). Females suffered significantly longer time interval from symptom onset to the admission to PCI center (3.3hrs vs 2.5hrs; p=0.001). In females, the primary net-clinical EP at 7 days was not different from males (4.4% vs 3.9%; p=0.645) but at 30 days, the rate of MI and combined key efficacy EP occurred significantly more often(5.4% vs 2.7%; p=0.030 [HR 5.234; 95% CI, 1.902-14.401] and 3.3% vs 0.6%; p=0.001 [HR 2.007 95% CI, 1.072-3.759], respectively). At 12 months, there was no significant difference between the groups, though a strong trend to higher rate of MI and bleeding was found (HR 1.968, 95% CI 0.985-3.929; p=0.055 and HR 1.399 95% CI 0.970-2.020; p=0.073, respectively). End of potent P2Y12 treatment within one year was observed more often in females than males, though not statistically significant (58.5% vs 52.0%; p=0.053). No significant difference was found in the economically driven switch to clopidogrel (43.1% vs 37.8%; p=0.103). Conclusions: In the PRAGUE-18 study, the female patients were at higher baseline clinical risk, had significantly higher rate of MI and cardiovascular death/MI/stroke at 30 days and tended to have a higher rate of repeated MI and bleeding complications at 12 months. Longer pre-hospital ischemic time in females requires special attention.
ER  -

KALA, Petr; Zuzana MOTOVSKA; Ota HLINOMAZ; Milan HROMADKA; Jiří KNOT; Ivo VARVAROVSKY; Jaroslav DUSEK; Roman MIKLIK; Jiří JARKOVSKÝ; Stanislav SIMEK; Marian BRANNY; Jan MROZEK; Pavel CERVINKA; Jiri OSTRANSKY; Richard ROKYTA; Frantisek TOUSEK and Petr WIDIMSKY. \textit{Gender Differences in the One-Year Outcomes of Prasugrel versus Ticagrelor in Acute Myocardial Infarction Treated With Primary Angioplasty: A Posthoc Analysis of the PRAGUE-18 Study}. 2018. ISSN~0009-7322.

Přehled o publikaci